Comparison between success rates for smokers re-treated by a smokers' clinic and success rates for smokers treated for the first time
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
32592219
DOI
10.1111/add.15175
Knihovny.cz E-resources
- Keywords
- Mental health, nicotine, pharmacotherapy, re-treatment, tobacco, tobacco dependence, tobacco use disorder, varenicline,
- MeSH
- Ambulatory Care Facilities MeSH
- Cohort Studies MeSH
- Smoking epidemiology MeSH
- Smokers statistics & numerical data MeSH
- Smoking Cessation Agents therapeutic use MeSH
- Humans MeSH
- Smoking Cessation methods MeSH
- Tobacco Use Disorder therapy MeSH
- Tobacco Use Cessation Devices statistics & numerical data MeSH
- Recurrence MeSH
- Retrospective Studies MeSH
- Varenicline therapeutic use MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Smoking Cessation Agents MeSH
- Varenicline MeSH
AIMS: To compare success rates and characteristics of smokers treated a second time by a smokers' clinic with success rates of their first treatment. DESIGN: Retrospective cohort study. SETTING: Tobacco Dependence Treatment clinic in Prague, Czech Republic, between 2005 and 2017. PARTICIPANTS: A total of 5225 smokers treated either once (n = 5006, single treatment sample, SS) or also second time (n = 219, re-treated sample, RS), on average 4.47 years after the first visit. INTERVENTION: Smokers received intensive treatment of tobacco dependence with pharmacotherapy options. Outcomes were evaluated after 1 year. In case of failure or relapse, participants could undergo re-treatment in the same setting at least 1 year after the start of the first treatment. MEASUREMENTS: Twelve-month self-reported continuous abstinence; CO-validated (≤ 6 parts per million); number of visits; type of pharmacotherapy; mental health history; Fagerström Test for Cigarette Dependence; time between first and second treatment. RESULTS: The abstinence rate in the SS was 34.8% [95% confidence interval (CI) = 33.4%, 36.1%] and in the RS was 37% (95% CI = 30.6%, 43.8%) and 39.7% (95% CI = 33.2%, 45.5%) for their first and second treatments, respectively. The samples were comparable on smoking and socio-demographic characteristics and pharmacotherapy used, but the RS in the second treatment had a higher prevalence of diagnosed mental health disorder at 39.3% (95% CI = 32.8%; 46.1%) compared with 23.7% (95% CI = 22.5%; 24.9%) in the SS. Participants who initiated their second quit attempt 1 to 2 years after the first one were less successful than those who initiated their second quit attempt later (25 versus 43%; P < 0.05). The results of the first treatment cycle were not found to be a reliable predictor for outcomes of the second cycle of treatment in univariate or multivariate logistic regression (odds ratio = 1.35, 95% CI = 0.70-2.63, P = 0.373). CONCLUSION: In Prague, Czech Republic, smokers re-attending stop-smoking treatment more than 2 years after their previous quit attempt appear to achieve similar success rates to those being treated for the first time.
See more in PubMed
American Cancer Society. Guide to Quitting Smoking. Available at: http://www.cancer.org/healthy/stayawayfromtobacco/guidetoquittingsmoking/guide-to-quitting-smoking-pdf (accessed 26 July 2013).
Ellerman A., Ford C., Stillman S. Smoking cessation: 7.7: personal factors associated with quitting. In: Scollo M., Winstanley M., editors. Tobacco in Australia: facts and issues, 3rd edn. Carlton, VIC: Cancer Council Victoria; 2008, p. 52.
US Department of Health and Human Services. Women and Smoking: a Report of the Surgeon General. Rockville, MD, 2001: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2001.
Chaiton M., Diemert L., Cohen J. E., Bondy S. J., Selby P., Philipneri A., et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open 2016; 6: e011045.
Gonzales D., Hajek P., Pliamm L., Nackaerts K., Tseng L. J., McRae T. D., et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clin Pharmacol Ther 2014; 96: 390-396.
Gonzales D. H., Nides M. A., Ferry L. H., Kustra R. P., Jamerson B. D., Segall N. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001; 69: 438-444.
Kautiainen K., Ekroos H., Puhakka M., Liira H., Laine J., Linden K., et al. Re-treatment with varenicline is a cost-effective aid for smoking cessation. J Med Econ 2017; 20: 246-252.
Annemans L., Marbaix S., Nackaerts K., Bartsch P. Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation. Prev Med Rep 2015; 14: 189-195.
Cahill K., Stevens S., Perera R., Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 5: CD009329.
Han E. S., Foulds J., Steinberg M. B., Gandhi K. K., West B., Richardson D. L., et al. Characteristics and smoking cessation outcomes of patients returning for repeat tobacco dependence treatment. Int J Clin Pract 2006; 60: 1068-1074.
Partos T. R., Borland R., Yong H. H., Hyland A., Cummings K. M. The quitting rollercoaster: how recent quitting history affects future cessation outcomes (data from the international tobacco control 4-country cohort study). Nicotine Tob Res 2013; 15: 1578-1587.
Bold K. W., Rasheed A. S., McCarthy D. E., Jackson T. C., Fiore M. C., Baker T. B. Rates and predictors of renewed quitting after relapse during a one-year follow-up among primary care patients. Ann Behav Med 2015; 49: 128-140.
Foulds J., Schmelzer A. C., Steinberg M. B. Treating tobacco dependence as a chronic illness and a key modifiable predictor of disease. Int J Clin Pract 2010; 64: 142-146.
Fiore M. C., Jaén C. R., Baker T. B., Bailey W. C., Curry S. J., Dorfman S. F., et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services; 2008, pp. 1-176.
Kralikova E., Ceska R., Pankova A., Stepankova L., Zvolska K., Felbrova V., et al. Doporucení pro lecbu zavislosti na tabaku. Vnitr Lek 2015; 61(5, Suppl 1): 1S4-1S15 (in Czech).
West R., Hajek P., Stead L., Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303.
Fucito M, Toll, B, Roos C, King A. Smokers’ treatment expectancies predict smoking cessation success. Published in final edited form as: J Smok Cessat 2016; 11: 143-149.
Gwaltney C. J., Metrik J., Kahler C. W., Shiffman S. Self-efficacy and smoking cessation: a meta-analysis. Psychol Addict Behav 2009; 23: 56-66.
Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerström test for cigarette dependence. Nicotine Tob Res 2012; 14: 75-78.
Royal College of Physicians (RCP) Smoking and Mental Health. Royal College of Psychiatrists Council Report CR178. London, UK: RCP; 2013, pp. 84-103.
Ziedonis D., Hitsman B., Beckham J. C., Zvolensky M., Adler L. E., Audrain-McGovern J. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 2008; 10: 1691-1715.
Rüther T., Bobes J., De Hert M., Svensson T. H., Mann K., Batra A., et al. European Psychiatric Association. EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry 2014; 29: 65-82.
